Search Results - "Wit, FW"

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study by van Leth, F, Phanuphak, P, Ruxrungtham, K, Baraldi, E, Miller, S, Gazzard, B, Cahn, P, Lalloo, UG, van der Westhuizen, IP, Malan, DR, Johnson, MA, Santos, BR, Mulcahy, F, Wood, R, Levi, GC, Reboredo, G, Squires, K, Cassetti, I, Petit, D, Raffi, F, Katlama, C, Murphy, RL, Horban, A, Dam, JP, Hassink, E, van Leeuwen, R, Robinson, P, Wit, FW, Lange, JMA

“…The 2NN Study was a randomised comparison of the non-nucleoside reverse-transcriptase inhibitors (NNRTI) nevirapine and efavirenz. In this multicentre,…”
Get full text

Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy by KESSELRING, Anouk M, WIT, Ferdinand W, MOCROFT, Amanda, SABIN, Caroline A, LUNDGREN, Jens D, GILL, M. John, GATELL, Jose M, RAUCH, Andri, MONTANER, Julio S, DE WOLF, Frank, REISS, Peter

“…This collaboration of seven observational clinical cohorts investigated risk factors for treatment-limiting toxicities in both antiretroviral-naive and…”
Get full text

Safe interruption of Maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy by KIRK, Ole, REISS, Peter, UBERTI-FOPPA, Caterina, BICKEL, Markus, GERSTOFT, Jan, PRADIER, Christian, WIT, Ferdinand W, LEDERGERBER, Bruno, LUNDGREN, Jens D, FURRER, Hansjakob

“…The safety of interrupting maintenance therapy for previous opportunistic infections other than Pneumocystis carinii pneumonia among patients with HIV…”
Get full text

Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy by Leth, F Van, Kappelhoff, B S, Johnson, D, Losso, M H, Boron-Kaczmarska, A, Saag, M S, Livrozet, J-M, Hall, D B, Leith, J, Huitema, A D R, Wit, F W, Beijnen, J H, Lange, J M A

“…Optimal adherence is essential for successful antiretroviral therapy. We analyzed the relation between minimum plasma drug concentration (Cmin) and total drug…”
Get more information

Mitochondrial DNA and RNA Increase in Peripheral Blood Mononuclear Cells from HIV-1–Infected Patients Randomized to Receive Stavudine-Containing or Stavudine-Sparing Combination Therapy by Casula, Miriam, Weverling, Gerrit Jan, Wit, Ferdinand W., Timmermans, Eveline C., Stek, Michael, Lange, Joep M., Reiss, Peter

“…BackgroundMitochondrial DNA (mtDNA) in peripheral blood mononuclear cells (PBMCs) has been suggested as a potential marker of mitochondrial toxicity associated…”
Get full text

Virologic and Immunologic Response to Highly Active Antiretroviral Therapy in Indigenous and Nonindigenous HIV-1–Infected Patients in The Netherlands by Nellen, Jeannine F, Wit, Ferdinand W, de Wolf, Frank, Jurriaans, Suzanne, Lange, Joep M, Prins, Jan M

“…OBJECTIVE:To compare the results of antiretroviral treatment (highly active antiretroviral therapy [HAART]) in indigenous Dutch (ID) and nonindigenous…”
Get full text

Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients by Pogány, K, Zaaijer, H L, Prins, J M, Wit, F W, Lange, J M A, Beld, M G H M

“…Occult hepatitis B virus (HBV) infection is diagnosed when HBc antibodies and HBV-DNA are detectable in serum while hepatitis B surface antigen (HBsAg) is not…”
Get more information

Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV‐infected patients with lipodystrophy according to a validated case definition by Casula, M, Van Der Valk, M, Wit, FW, Nievaard, MA, Reiss, P

“…Background Several studies have compared mitochondrial DNA (mtDNA) content in tissue from HIV‐1‐infected patients on highly active antiretroviral therapy with…”
Get full text